Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for ?6 million on September 20, 2022. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year. Pierre-Olivier Mahieu and Sophie Rutten of Allen & Overy LLP (Brussels) acted as legal advisor to Celyad Oncology SA (ENXTBR:CYAD).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3005 EUR | -3.06% | -4.15% | -22.95% |
04-04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.95% | 13.51M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA for ?6 million.